All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Chemotherapy represents the first-line approach for cancer treatment, yet side-effects remain significant. One such side-effect is mucositis, which results from a series of biological events initiated by the epithelial cell response to cytotoxic damage \[[@pone.0158851.ref001]\]. Certain cytotoxic drugs are more commonly associated with mucositis development; the chemotherapy drug 5-fluorouracil is one such agent \[[@pone.0158851.ref002]\]. Mucositis affects all mucous-membrane covered surfaces from the mouth to the rectum, and remains the main dose limiting factor in cancer treatment \[[@pone.0158851.ref003], [@pone.0158851.ref004]\].

Mucositis is thought to be the resultant effect of a range of cytokine-mediated events culminating in mucosal atrophy and ulceration \[[@pone.0158851.ref005]\]. Epithelial sloughing, mucosal inflammation and ulceration activate nociceptors causing a direct pain response \[[@pone.0158851.ref006]\]. Additionally, pain may arise as a sequela of other gastrointestinal events such as abdominal bloating or a change in bowel pattern \[[@pone.0158851.ref007]\]. Accordingly, patients typically require potent opioid analgesics for pain control during extended periods of hospitalisation \[[@pone.0158851.ref006]\].

Rats are frequently used as models in alimentary mucositis disease investigations, in order to elucidate pathogenesis of the condition or to trial new therapeutics \[[@pone.0158851.ref008]\]. It has previously been demonstrated that rats with chemotherapy-induced mucositis undergo pathophysiological changes, \[[@pone.0158851.ref009], [@pone.0158851.ref010]\] and exhibit behavioural signs indicative of pain \[[@pone.0158851.ref011]\]. However, analgesic use is never reported in publications involving animal models of mucositis. It is therefore unknown if analgesics commonly used in laboratory animal practice are efficacious against the pain evoked by mucositis, or whether they impact on commonly measured experimental outcomes, and hence would confound future study interpretation.

Consequently, the current study employed a rat model of mucositis induced by 5-Fluorouracil to characterize the effect of three clinically relevant veterinary analgesics on the affective component of the pain response, gut mucosal architecture and inflammatory response. Agents chosen were: buprenorphine, a partial μ opiate agonist, \[[@pone.0158851.ref012]\] with moderate analgesic effect and fewer side-effects than pure μ agonists \[[@pone.0158851.ref013]\]; tramadol, an 'atypical' opioid analgesic which exerts its action via both opioid (μ receptor) and non-opioid (inhibition of monoamine uptake) mechanisms \[[@pone.0158851.ref014]\]; and the selective COX-2 inhibitor Non-Steroidal Anti-Inflammatory Drug (NSAID), carprofen \[[@pone.0158851.ref015]\].

Materials and Methods {#sec002}
=====================

Animals and Experimental Design {#sec003}
-------------------------------

Female Dark Agouti rats (110-140g, n = 64) were sourced from a barrier-maintained Specific-Pathogen Free production facility (Laboratory Animal Services, the University of Adelaide, Adelaide, SA, Australia). Female rats were selected for this study since they are commonly used in mucositis disease investigations and thus results of this study would find general practical applicability \[[@pone.0158851.ref008]\]. On arrival, animals were group-housed in standard open-top polycarbonate rat cages of dimensions 415 mm x 260 mm x 145 mm (Tecniplast, NSW, Australia). Rats remained in these cages for an acclimatisation period of 5 days with *ad libitum* access to potable reverse osmosis treated water and a standard rat chow (Speciality Feeds, Glenn Forest, WA). Room temperature was maintained at 21--23°C with a 12 hr reversed light-dark cycle (lights off at 0800). Red light was provided to facilitate making observations from video-records in the darkness. Following acclimatisation, animals were transferred to individual housing in metabolic cages (Tecniplast. Exton, PA, US). *Ad libitum* access to food and water continued in these cages but the diet was changed to an 18% casein-based diet \[[@pone.0158851.ref009], [@pone.0158851.ref016]\] to be consistent with previously published papers in this area. \[[@pone.0158851.ref009]\]

Rats were randomly allocated to eight groups (n = 8): Saline injection (0.9% NaCl w/v), carprofen (15 mg/kg) + saline, buprenorphine (0.05 mg/kg) + saline, tramadol (12.5 mg/kg) + saline, 5-Fluorouracil (5-FU) injection carprofen (15 mg/kg) + 5-FU, buprenorphine (0.05mg/kg) + 5-FU, tramadol (12.5 mg/kg) + 5-FU. Experimental design was standardized with previous studies evaluating novel therapeutic agents for the treatment of chemotherapy-induced mucositis \[[@pone.0158851.ref009], [@pone.0158851.ref017]\]. All animal handling and drug administration procedures were performed as described in reputable guidance documents \[[@pone.0158851.ref018]\]. Rats were metabolic-cage housed on study days 0--9. Acclimatization to metabolic cages occurred on experimental days 0--2 with data recording commencing on day 3. On day 6, manually restrained animals received an intraperitoneal injection of 5-FU (150 mg/kg; Mayne Pharma Pty, Ltd, Mulgrave, Vic, Australia) or an equivalent volume of saline. At this time analgesic treatments were commenced depending on group allocation. All analgesics were injected subcutaneously into the scapular region. Analgesics were given as per clinical practice and were continued at 12 hourly intervals for the remainder of the study (a total of 6 doses). Animals were continuously video-recorded in their home metabolic cages using closed-circuit television (CCTV) cameras (OzSpy CLOC 600IR) mounted behind each cage (one camera per cage).

Body weight, food and water intake and urine output were measured daily. Rats were humanely killed by overdose of CO~2~ on day 9 (72 hours after 5-FU or saline injection). Blood was obtained via cardiac puncture and collected into lithium heparin coated blood collection tubes. All visceral organs were weighed. Gastrointestinal organs were weighed following content removal by gentle expression using a smooth edged spatula on an ice-cooled slab. Lengths of the duodenum, small intestine and colon were measured un-stretched. Sections (2 cm) of the gastrointestinal organs were collected and placed in 10% buffered formalin for histological analysis. Further (4 cm) samples were snap frozen in liquid nitrogen and stored at -80°C for later biochemical analysis. Animal housing and experimental protocols were approved by the Animal Ethics Committee of the University of Adelaide and conducted in accordance with the provisions of the Australian Code for the Care and Use of Animals for Scientific Purposes \[[@pone.0158851.ref019]\].

Behavioural Data Analysis {#sec004}
-------------------------

Behavioural scoring was conducted on the continuously recorded home cage data by one person in a blinded fashion using analysis software (Cowlog, University of Helsinki, Helsinki, Finland) \[[@pone.0158851.ref020]\]. The occurrences of a number of behaviours previously shown to be associated with abdominal pain were scored over a 10 minute period at each of 3 time-points in the dark phase of the circadian cycle; 12 hours prior to 5-FU injection and 48 hr and 50 hours post-injection \[[@pone.0158851.ref021], [@pone.0158851.ref022]\]. The latter two time points were selected to include an observation point just prior to analgesic injection and 2 hours following injection. Frequency only, or frequency and duration, was scored based on the characteristics of the behaviour being observed. The ethogram used is illustrated in [Table 1](#pone.0158851.t001){ref-type="table"}. Sampling method, behaviours scored and time points observed were selected based on a previous exploratory study in which maximal frequency of pain behaviours was demonstrated to occur at 48 hours post-chemotherapy injection \[[@pone.0158851.ref011]\].

10.1371/journal.pone.0158851.t001

###### Ethogram for in-cage behavioural analysis (adapted from Roughan and Flecknell, 2001 \[[@pone.0158851.ref021]\]).

![](pone.0158851.t001){#pone.0158851.t001g}

  Behaviour            Description
  -------------------- -----------------------------------------------------------
  Attend               Movement vibrissae accompanying head lifting
  Back Arch            Arching of back ('cat stretch')
  Abdominal Groom      Grooming
  High Rear            Standing on hindlegs
  Sleep                Inactivity for \> 90s
  Sniff                Movement of vibrissae
  Stagger/fall         Loss of balance whilst walking or falling whilst grooming
  Stop                 Transient inactivity \<90s
  Horizontal Stretch   Elongation of the body with paws reaching above head
  Turn                 Turning without movement in any direction
  Twitch               Contraction of back muscles
  Walk                 Walking
  Writhe               Lateral contortion of flank muscles
  Yawn                 Yawning

Myeloperoxidase (MPO) Assay {#sec005}
---------------------------

Tissue samples (4 cm) of the jejunum and ileum were thawed on ice and homogenized with 1.5 mL of phosphate buffer (10 mM, pH 6.1) for 60 seconds until a homogenous solution was obtained. Homogenized samples were kept at −80°C until required. MPO levels were determined using the assay described by Krawisz *et al*. *1984* \[[@pone.0158851.ref023]\]. Homogenates were thawed on ice and centrifuged at 13000 g for 13 min. Following removal of the supernatant the cell pellets were re-suspended in hexadecyltrimethyl ammonium bromide (0.5%, pH 6.0). Samples were then vortexed for 2 min and centrifuged at 13000 g for 3 min. Supernatants were collected into a 96- well plate and reacted with *o*-dianisidine. Absorbance was measured at 450 nm at 1 min intervals for a period of 15 min using a microplate reader (Sunrise Microplate Reader, Tecan Austria GmbH, Grodig, Austria). A pre-designed excel macro was used to calculate MPO activity. Activity was expressed as units MPO per gram of tissue.

Blood Biochemistry {#sec006}
------------------

Blood samples were centrifuged at 4000 *g* for 6 min, the plasma supernatant removed and immediately analyzed for biochemical parameters using Beckman Coulter reagents (Beckman Coulter AU480, NSW, Australia) at a commercial diagnostic lab (Veterinary Diagnostics Laboratory, The University of Adelaide, Australia). Analyses included albumin, alkaline phosphatase (ALP), alanine transaminase (ALT), amylase, Ca:P ratio, creatinine kinase, creatinine, glucose, Na:K ratio, total protein and urea.

Histological Analysis {#sec007}
---------------------

Tissue samples were fixed in formalin for 24 h and then placed in 70% ethanol. Transverse tissue sections (4 μm) were embedded in paraffin wax, H&E stained and viewed using a light microscope (Olympus CX-41; Olympus, Tokyo, Japan). The disease severity score was determined semi-quantitatively by scoring eight independent histological criteria. The method used represented a slight modification of that described by Howarth *et al*. 1996 \[[@pone.0158851.ref024]\]. The criteria scored were: villus blunting, crypt distortion, reduction in goblet cell number, dilation of lymphatics, thickening of the submucosa, thickening of the muscularis externa, enterocyte disruption and lymphocytic cell infiltration. Each criterion was scored from zero (normal) to three (maximal damage) and expressed as a median score. Saline control rat intestinal tissue was used as a baseline reference to grade the criteria. Villus heights and crypt depths (40 villi and 40 crypts per section) were determined in the jejunal and ileal sections using a light microscope (Nikon, ProgRes®CS, Tokyo, Japan) and image ProPlus software version 5.1 (Media Cybernetics, Silver Spring MD, USA). All histological analyses were conducted in a blinded fashion.

Statistical Analyses {#sec008}
--------------------

Statistical analyses were conducted using PASW 21 (SPSS, Inc., Chicago, IL, USA) and Megastat Excel Add-In (version 10.2, McGraw-Hill Higher Education, New York, NY). Data were tested for normality and homogeneity of variance using the Shapiro--Wilk test. Parametric data were compared using one-way analysis of variance (ANOVA) with a Tukey\'s *post-hoc* test and presented as means ± standard error of the mean. Disease severity score and serum biochemistry were analysed by a Kruskal-Wallis test with a Mann Whitney U-test to determine between-group significance. Rat behavioural data were also non-parametric and analyzed similarly with both between, and within group comparisons made. Non-parametric data are shown as medians and ranges. Significance was determined at *p* \< 0.05 with Bonferroni corrections made where appropriate to account for multiple comparisons.

Results {#sec009}
=======

Daily Metabolic Parameters and Bodyweight {#sec010}
-----------------------------------------

Following saline or 5-FU injection there were significant differences between the groups in a number of the clinical parameters recorded ([Table 2](#pone.0158851.t002){ref-type="table"}; see also [S1 File](#pone.0158851.s001){ref-type="supplementary-material"}). In the analgesic control groups receiving saline injection, both buprenorphine and tramadol resulted in a decrease in bodyweight with no concomitant decrease in food consumption. Bodyweights of animals in the remaining treatment groups demonstrated an increase. Buprenorphine administration increased water intake and consequently urine output ([Table 2](#pone.0158851.t002){ref-type="table"}).

10.1371/journal.pone.0158851.t002

###### Effects of analgesic agents on cumulative bodyweight change, food and water intake and urine output in saline-injected rats and in 5-FU injected rats from days 7--9.

Data are expressed as means ± SEM.

![](pone.0158851.t002){#pone.0158851.t002g}

                                                                 saline alone   saline + carprofen                                 saline + buprenorphine                             saline + tramadol                                 5-FU alone                                         5-FU + carprofen                                   5-FU + buprenorphine                                                                   5-FU +tramadol
  -------------------------------------------------------------- -------------- -------------------------------------------------- -------------------------------------------------- ------------------------------------------------- -------------------------------------------------- -------------------------------------------------- -------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------
  Body Weight Change (%)[^§^](#t002fn003){ref-type="table-fn"}   3.4 ± 1.1      3.6 ± 0.5                                          -0.3 ± 0.9[\*](#t002fn001){ref-type="table-fn"}    -1.4 ± 0.3[\*](#t002fn001){ref-type="table-fn"}   -4.2 ± 0.6[\*](#t002fn001){ref-type="table-fn"}    -5.9 ± 0.4[\*](#t002fn001){ref-type="table-fn"}    -7.2 ± 0.8[†](#t002fn002){ref-type="table-fn"}[\*](#t002fn001){ref-type="table-fn"}    -10.2 ± 0.5[†](#t002fn002){ref-type="table-fn"}[\*](#t002fn001){ref-type="table-fn"}
  Mean Daily Water Intake (ml/gbw)                               0.18 ± 0.02    0.19 ± 0.04                                        0.43 ± 0.10[\*](#t002fn001){ref-type="table-fn"}   0.26 ± 0.06                                       0.23 ± 0.03                                        0.29 ± 0.03                                        0.54 ± 0.10[\*](#t002fn001){ref-type="table-fn"}[†](#t002fn002){ref-type="table-fn"}   0.50 ± 0.07[\*](#t002fn001){ref-type="table-fn"}[†](#t002fn002){ref-type="table-fn"}
  Mean Daily Food Intake (g/gbw)                                 0.08 ± 0.01    0.06 ± 0.01                                        0.06 ± 0.01[\*](#t002fn001){ref-type="table-fn"}   0.06 ± 0.01                                       0.03 ± 0.01[\*](#t002fn001){ref-type="table-fn"}   0.03 ± 0.01[\*](#t002fn001){ref-type="table-fn"}   0.03 ± 0.01[\*](#t002fn001){ref-type="table-fn"}                                       0.02 ± 0.01[\*](#t002fn001){ref-type="table-fn"}
  Mean Daily Urine Output (ml/gbw)                               0.09 ± 0.01    0.20 ± 0.05[\*](#t002fn001){ref-type="table-fn"}   0.21 ± 0.05[\*](#t002fn001){ref-type="table-fn"}   0.10 ± 0.01                                       0.16 ± 0.02                                        0.16 ± 0.02                                        0.34 ± 0.07[\*](#t002fn001){ref-type="table-fn"}[†](#t002fn002){ref-type="table-fn"}   0.49 ± 0.05[\*](#t002fn001){ref-type="table-fn"}[†](#t002fn002){ref-type="table-fn"}

\* indicates statistical significance compared to saline at *p* \< 0.05.

† indicates statistical significance compared to 5-FU alone at *p* \< 0.05.

§ Bodyweight change is expressed as the mean total % change calculated in relation to the baseline weight recorded at the time of saline/5-FU injection.

Administration of 5-FU significantly reduced bodyweight and food intake compared to saline injected rats ([Table 2](#pone.0158851.t002){ref-type="table"}). In the rats administered either buprenorphine or tramadol in combination with 5-FU the analgesic agents potentiated this weight loss compared to the 5-FU control group (↑72%, *p* = 0.005; ↑143%, *p* \< 0.001 respectively). Again, notably, this bodyweight decrease was not accompanied by a significant decrease in food intake (*p =* 0.99 for both analgesic agents). Buprenorphine and tramadol administration to 5-FU injected rats increased water consumption in comparison to 5-FU control animals by 135% (*p* = 0.002) and 117% (*p* = 0.003) respectively. Correspondingly, urine output was increased in animals receiving these analgesics.

Behavioural Assessment Scoring {#sec011}
------------------------------

In general, the specific pain behaviours of interest were observed at low frequencies, hence the behaviours that had previously been shown to increase in mucositis \[[@pone.0158851.ref011]\] were amalgamated to form a composite pain score, as described previously \[[@pone.0158851.ref025], [@pone.0158851.ref026]\]. This score consisted of back arch, horizontal stretch, stagger, twitch and writhe. Whilst it is known that metabolic cage housing does evoke changes in animal behaviour \[[@pone.0158851.ref027], [@pone.0158851.ref028]\] the consistent use of these cages across all treatment groups should have minimized any confounding influence of the cages themselves on behavioural outcomes.

Whilst all analgesic agent-treated groups demonstrated significant decreases in score when compared to animals that received 5-FU alone at either the 48 hour or 50 hour time point, with the exception of buprenorphine (50 hours) these values were not significant in comparison to saline controls alone ([Fig 1](#pone.0158851.g001){ref-type="fig"}; see also [S2 File](#pone.0158851.s002){ref-type="supplementary-material"}). However, on comparing scores within groups between the time points a significant difference was only recorded with the 5-FU control animals between baseline and 48 hours (*p* = 0.01) indicating that in all other groups they either experienced no change in pain level, or that pain was effectively treated.

![Effect of analgesic agents on composite pain score prior to injection, and 48hr and 50 hours after injection; (A) saline injection (B) 5-FU injection. The box plots represent the first and third quartiles, horizontal lines represent the median pain score and the whisker ends represent 1.5 x inter-quartile range, X represent outlying points. \* indicates *p* \< 0.05 compared to saline + no analgesic and † *p* \< 0.05 compared to 5-FU + no analgesic between groups within the same time point. § represents significant difference at p = 0.008 between time points within the same group.](pone.0158851.g001){#pone.0158851.g001}

There was less consistency in the frequency of performance of the other measured behaviours ([Table 3](#pone.0158851.t003){ref-type="table"}; see also [S2 File](#pone.0158851.s002){ref-type="supplementary-material"}) and there was significant inter-animal variability. Key changes included that high rearing increased between baseline and 50 hours in the 5-FU alone group (*p* = 0.03) and sleep duration increased between baseline and 48 hours in the buprenorphine treated animals with mucositis (*p* = 0.01). The converse was observed for tramadol treated animals (*p* = 0.03).

10.1371/journal.pone.0158851.t003

###### Effect of analgesic agents on non-pain specific behaviours.

Data are expressed as median (interquartile range) of behavioural frequency over 10 minute observation period unless duration indicated.
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                       saline alone   saline + carprofen                                    saline + buprenorphine   saline + tramadol                                                                                5-FU alone                                                5-FU + carprofen                                              5-FU + buprenorphine                                                             5-FU +tramadol
  -------------------- -------------- ----------------------------------------------------- ------------------------ ------------------------------------------------------------------------------------------------ --------------------------------------------------------- ------------------------------------------------------------- -------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------
  ***Baseline***                                                                                                                                                                                                                                                                                                                                                                                                               
  High rear            0 (2)          0 (0)                                                 1 (3.5)                  0 (0)                                                                                            0 (0)[§](#t003fn003){ref-type="table-fn"} ^(base,\ 50)^   0 (0)[\*](#t003fn001){ref-type="table-fn"}                    0 (2)                                                                            1(0.75)
  Abdominal groom      2.5 (4)        1 (0.5)                                               1 (1)                    0 (0)                                                                                            0.5 (2.5)                                                 0 (0)                                                         2.5 (2.5)                                                                        1 (0.75)
  Stop                 2 (3.5)        1 (1.5)                                               2 (3.5)                  0 (3)                                                                                            3.5 (2.25)                                                0 (0.5)[†](#t003fn002){ref-type="table-fn"}                   3 (3.75)                                                                         6 (1.5)[\*](#t003fn001){ref-type="table-fn"}
  Sleep Duration (s)   364 (563)      516 (237)                                             149 (295)                600 (185)                                                                                        377 (230)                                                 490 (179)                                                     79 (247)                                                                         290 (219)
  ***48 Hours***                                                                                                                                                                                                                                                                                                                                                                                                               
  High rear            0 (0)          0 (0)[§](#t003fn003){ref-type="table-fn"} ^(48,50)^   0 (1)                    0 (2.5)                                                                                          0 (0.5)                                                   0 (0)                                                         0 (0)                                                                            0 (0)
  Abdominal groom      1 (2)          1 (1)                                                 0 (2)                    1 (1.5)                                                                                          0.1 (2)                                                   1.5 (3)                                                       0 (0.5)                                                                          1 (1)
  Stop                 0.5 (4.5)      0 (1.5)                                               1 (3.5)                  5 (5.5)[\*](#t003fn001){ref-type="table-fn"}[§](#t003fn003){ref-type="table-fn"} ^(base,\ 48)^   4 (2)                                                     4.5 (3.25)[§](#t003fn003){ref-type="table-fn"}^(base,\ 48)^   1 (0.75)[†](#t003fn002){ref-type="table-fn"}                                     4.5 (5.25)
  Sleep Duration       402 (333)      478 (129)                                             582 (597)                0 (194)[\*](#t003fn001){ref-type="table-fn"}                                                     402 (143)                                                 177 (440)                                                     543 (185)[§](#t003fn003){ref-type="table-fn"} ^(base,\ 48)^                      0 (0)[†](#t003fn002){ref-type="table-fn"}[§](#t003fn003){ref-type="table-fn"}^(base,\ 48)^
  ***50 Hours***                                                                                                                                                                                                                                                                                                                                                                                                               
  High rear            1 (2)          1 (2.5)                                               0 (0)                    0 (0)                                                                                            1.5 (5.5)                                                 0 (0.5)                                                       0 (0.5)                                                                          0.5 (2.5)
  Abdominal groom      2 (0.75)       2 (4)                                                 0 (0)                    1 (2)                                                                                            1 (1.75)                                                  1 (1.5)                                                       0 (0)[\*](#t003fn001){ref-type="table-fn"}[†](#t003fn002){ref-type="table-fn"}   0.5 (1.5)
  Stop                 3 (2.25)       2 (2.5)                                               1 (2.5)                  4 (5)                                                                                            5.5 (3.75)                                                1.5 (2.5)                                                     3 (3)                                                                            2.5 (5.25)
  Sleep Duration       46 (292)       157 (302)                                             534 (109)                415 (433)                                                                                        98 (94)                                                   366 (183)                                                     337 (252)                                                                        63.5 (177)

\* indicates statistical significance at *p* \< 0.05 compared to saline alone.

† indicates statistical significance at *p* \< 0.05 compared to 5-FU alone.

§ represents significant difference between time points within the same group, superscript value shows the time points that are statistically different.

Organ Weights {#sec012}
-------------

In healthy analgesic control animals, carprofen increased liver weight by 12% in comparison to saline alone control animals (*p* = 0.04). Alternately, buprenorphine decreased liver weight by 10% (*p* = 0.03, [Table 4](#pone.0158851.t004){ref-type="table"}). Administration of 5-FU significantly reduced thymus weight by 60% (*p* \< 0.001) and spleen weight by 20% (*p* \< 0.001) compared to saline-injected rats ([Table 4](#pone.0158851.t004){ref-type="table"}). Both buprenorphine and tramadol administration exacerbated the 5-FU induced decrease in thymic weight. Carprofen elevated renal weights (\~↑20%, p ≤ 0.001) whilst the converse was observed with tramadol (↓12%, *p* = 0.01) compared to 5-FU control ([Table 4](#pone.0158851.t004){ref-type="table"}; see also [S1 File](#pone.0158851.s001){ref-type="supplementary-material"}). Administration of 5-FU had no effect on liver mass. Analogously, carprofen led to an increase in liver weight (11%, *p* = 0.006) in comparison to 5-FU control animals, whilst tramadol decreased liver weight (11%, p = 0.02). However, buprenorphine when co-administered with 5-FU failed to produce liver mass changes.

10.1371/journal.pone.0158851.t004

###### Effects of analgesic agents on visceral organ weights of female Dark Agouti rats 72 hr after 5-FU or saline injection.

Organ weights were calculated as % (wtg/g/bwt) and are expressed as mean % ± SEM. All values are x 10^−2^.
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                   saline alone   saline + carprofen                             saline + buprenorphine                         saline + tramadol   5-FU alone                                    5-FU + carprofen                                                                   5-FU + buprenorphine                                                             5-FU +tramadol
  ---------------- -------------- ---------------------------------------------- ---------------------------------------------- ------------------- --------------------------------------------- ---------------------------------------------------------------------------------- -------------------------------------------------------------------------------- ----------------------------------------------------------------------------------
  Thymus           20 ± 1         20 ± 2                                         17± 1                                          20 ± 1              8 ± 1[\*](#t004fn001){ref-type="table-fn"}    8 ± 1[\*](#t004fn001){ref-type="table-fn"}                                         5 ± 1[\*](#t004fn001){ref-type="table-fn"}[†](#t004fn002){ref-type="table-fn"}   6 ± 1[\*](#t004fn001){ref-type="table-fn"}[†](#t004fn002){ref-type="table-fn"}
  Liver            393 ± 12       440 ± 9[\*](#t004fn001){ref-type="table-fn"}   357 ± 6[\*](#t004fn001){ref-type="table-fn"}   389 ± 22            388 ± 1                                       429 ± 9[\*](#t004fn001){ref-type="table-fn"}[†](#t004fn002){ref-type="table-fn"}   381 ± 9                                                                          347 ± 9[\*](#t004fn001){ref-type="table-fn"}[†](#t004fn002){ref-type="table-fn"}
  Spleen           21 ± 1         23 ± 1[\*](#t004fn001){ref-type="table-fn"}    23 ± 1                                         21 ± 1              17 ± 1[\*](#t004fn001){ref-type="table-fn"}   18 ± 1[\*](#t004fn001){ref-type="table-fn"}                                        15 ± 1[\*](#t004fn001){ref-type="table-fn"}                                      16 ± 1[\*](#t004fn001){ref-type="table-fn"}
  Left Kidney      41 ± 1         47 ± 1[\*](#t004fn001){ref-type="table-fn"}    42 ± 1                                         41 ± 2              44 ± 1                                        50 ± 1[\*](#t004fn001){ref-type="table-fn"}[†](#t004fn002){ref-type="table-fn"}    47 ± 2[\*](#t004fn001){ref-type="table-fn"}                                      39 ± 2[†](#t004fn002){ref-type="table-fn"}
  Right Kidney     43 ± 1         48 ± 1[\*](#t004fn001){ref-type="table-fn"}    43 ± 1                                         42 ± 2              45 ± 1                                        50 ± 1[\*](#t004fn001){ref-type="table-fn"}[†](#t004fn002){ref-type="table-fn"}    49 ± 1[\*](#t004fn001){ref-type="table-fn"}                                      40 ± 1[†](#t004fn002){ref-type="table-fn"}
  Adrenal Glands   2 ± 0.1        2 ± 0.3                                        2 ± 0.1                                        2 ± 0.1             2 ± 0.1                                       3 ± 0.1                                                                            3 ± 0.1                                                                          3 ± 0.1

\* indicates statistical significance at *p* \< 0.05 compared to saline alone.

† indicates statistical significance at *p* \< 0.05 compared to 5-FU alone.

5-FU significantly reduced the gastrointestinal organ lengths such that a 9% reduction was evident in the jejuno-ileum (*p* = 0.01) and an 11% reduction in the colon (*p* = 0.03) ([Table 5](#pone.0158851.t005){ref-type="table"}; see also [S1 File](#pone.0158851.s001){ref-type="supplementary-material"}). The analgesic agents had minimal moderating effect on organ lengths except for tramadol which attenuated the reduction in colon length produced by 5-FU (*p* = 0.02). However, all analgesic agents produced a reduction in weight of the jejuno-ileum when compared to 5-FU controls. A similar effect was observed in colon weights although this did not attain significance in the 5-FU + carprofen group (*p* = 0.08).

10.1371/journal.pone.0158851.t005

###### Effects of analgesic agents on gastrointestinal organ weights and lengths of female Dark Agouti rats 72 hr after 5-FU or saline injection.

Organ weights were calculated as % (wtg/g/bwt) and are expressed as mean % ± SEM. Lengths were measured in cm and are presented as mean ± SEM.
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                                 saline alone   saline + carprofen                             saline + buprenorphine                          saline + tramadol                               5-FU alone                                        5-FU + carprofen                                                                   5-FU + buprenorphine                                                               5-FU +tramadol
  ------------------------------ -------------- ---------------------------------------------- ----------------------------------------------- ----------------------------------------------- ------------------------------------------------- ---------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ----------------------------------------------------------------------------------
  **jejenum + ileum**                                                                                                                                                                                                                                                                                                                                                                                                  
  **Weight (x10**^**-2**^**)**   300 ± 10       246 ± 6[\*](#t005fn001){ref-type="table-fn"}   224 ± 10[\*](#t005fn001){ref-type="table-fn"}   229 ± 10[\*](#t005fn001){ref-type="table-fn"}   250 ± 6[\*](#t005fn001){ref-type="table-fn"}      223 ± 3[\*](#t005fn001){ref-type="table-fn"}[†](#t005fn002){ref-type="table-fn"}   200 ± 4[\*](#t005fn001){ref-type="table-fn"}[†](#t005fn002){ref-type="table-fn"}   200 ± 8[\*](#t005fn001){ref-type="table-fn"}[†](#t005fn002){ref-type="table-fn"}
  **length**                     70.5 ± 1.8     72.1 ± 0.5                                     73.3 ± 0.7                                      74.6 ± 1.7                                      64.8 ± 2.3[\*](#t005fn001){ref-type="table-fn"}   61.3 ± 0.9[\*](#t005fn001){ref-type="table-fn"}                                    63 ± 1.9[\*](#t005fn001){ref-type="table-fn"}                                      66.8 ± 1.8
  **colon**                                                                                                                                                                                                                                                                                                                                                                                                            
  **Weight(x10**^**-2**^**)**    70 ± 10        64 ± 2[\*](#t005fn001){ref-type="table-fn"}    65 ± 3                                          63 ± 5[\*](#t005fn001){ref-type="table-fn"}     70 ± 3                                            67 ± 2                                                                             62 ± 3[\*](#t005fn001){ref-type="table-fn"}[†](#t005fn002){ref-type="table-fn"}    60 ± 3[\*](#t005fn001){ref-type="table-fn"}[†](#t005fn002){ref-type="table-fn"}
  **length**                     14.4 ± 0.7     14.3 ± 0.4                                     14.9 ± 0.5                                      15.1 ± 0.6                                      12.8 ± 0.6[\*](#t005fn001){ref-type="table-fn"}   11.0 ± 0.2[\*](#t005fn001){ref-type="table-fn"}                                    12.7 ± 0.5[\*](#t005fn001){ref-type="table-fn"}                                    14.4 ± 0.4[†](#t005fn002){ref-type="table-fn"}

\* indicates statistical significance at *p* \< 0.05 compared to saline alone.

† indicates statistical significance at *p* \< 0.05 compared to 5-FU alone.

Serum Biochemistry {#sec013}
------------------

Serum biochemistry results are reported in [Table 6](#pone.0158851.t006){ref-type="table"}. Not all biochemical parameters were available for the tramadol-treated groups. When compared with saline controls, 5-FU caused statistically significant differences in creatinine kinase (CK) and creatinine values. However, these changes were unlikely to be of clinical significance. Noteworthy changes included; the elevation in creatinine in all 5-FU treated groups, and the depression in total protein in animals receiving the combination of 5-FU and carprofen. The consistent depression in urea was likely to be attributable to the specific analyzer used. It should be noted that serum biochemistry reference ranges for Dark Agouti rats were not available.

10.1371/journal.pone.0158851.t006

###### Effects of analgesic agents on blood biochemistry values of female Dark Agouti rats 72 hr after 5-FU or saline injection.

Data are expressed as median values with experimental group range in brackets. Shaded results are outside references range values given by Giknis and Clifford, 2008 (Charles River labs for inbred Wistars).

![](pone.0158851.t006){#pone.0158851.t006g}

                               saline alone       saline + carprofen                                                                        saline + buprenorphine                                                                  saline + tramadol   5-FU alone                                             5-FU + carprofen                                                                          5-FU + buprenorphine                                                                      5-FU + tramadol                                                                           Ref Interval
  ---------------------------- ------------------ ----------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ------------------- ------------------------------------------------------ ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- --------------
  Alkaline phosphatase (U/L)   77.0 (32--135)     114.0 (99--135) [†](#t006fn002){ref-type="table-fn"}                                      99.5 (85--115)                                                                          \-                  60.5 (42--139)                                         63.0(60--85)                                                                              64.5 (57--71)                                                                             \-                                                                                        26--147
  Alanine Transaminase(U/L)    42.0 (24--46)      51.0 (38--61) [†](#t006fn002){ref-type="table-fn"}                                        46.0 (31--69) [†](#t006fn002){ref-type="table-fn"}                                      \-                  30.0 (18--42)                                          29.0 (21--40)                                                                             40.5 (33--56)                                                                             \-                                                                                        16--48
  Amylase (U/L)                399.0 (380--546)   380.0 (316--1040)                                                                         385.0 (295--399) [†](#t006fn002){ref-type="table-fn"}                                   \-                  553.0 (371--645)                                       509.0 (446--776)                                                                          451.0 (389--550)                                                                          \-                                                                                        NA
  Ca:P ratio                   0.8 (0.6--1.1)     0.8 (0.7--0.8)                                                                            0.7 (0.5--0.9)                                                                          \-                  0.9 (0.5--1.2)                                         0.8 (0.7--0.8)                                                                            0.7 (0.4--0.8)                                                                            \-                                                                                        NA
  Creatinine Kinase (U/L)      631 (255--1776)    304 (188--599)                                                                            428 (120--700)                                                                          \-                  300 (98--1182)[\*](#t006fn001){ref-type="table-fn"}    444 (230--2019)                                                                           346 (165--1222)                                                                           \-                                                                                        163--1085
  Creatinine (μmol/L)          21.9 (18--27)      21.5 (19--24)                                                                             27.5 (22--39)                                                                           26.0 (21--31)       28.0 (20.6--33)[\*](#t006fn001){ref-type="table-fn"}   26.0 (23--31)[\*](#t006fn001){ref-type="table-fn"}                                        34.5 (28--45) [\*](#t006fn001){ref-type="table-fn"}[†](#t006fn002){ref-type="table-fn"}   32.2 (28--41) [\*](#t006fn001){ref-type="table-fn"}[†](#t006fn002){ref-type="table-fn"}   11--33
  Glucose (mmol/L)             7.0 (5--10)        10 (7--13)                                                                                12.0 (7--13)[\*](#t006fn001){ref-type="table-fn"}[†](#t006fn002){ref-type="table-fn"}   \-                  7.3 (3--10)                                            9.5(7--12)                                                                                9.5 (6--16) [†](#t006fn002){ref-type="table-fn"}                                          \-                                                                                        4.2--9.7
  Na:K ratio                   22.4 (18--26)      20.8 (20--29)                                                                             20.4 (18--23) [†](#t006fn002){ref-type="table-fn"}                                      \-                  24.6 (20--30)                                          25.9 (20--29)                                                                             24.3 (20--25)                                                                             \-                                                                                        NA
  Total Protein (g/L)          58.0 (55--64)      51.5 (50--56) [\*](#t006fn001){ref-type="table-fn"}[†](#t006fn002){ref-type="table-fn"}   59.0 (55--62)                                                                           \-                  59.0 (52--63)                                          48.5 (43--57) [\*](#t006fn001){ref-type="table-fn"}[†](#t006fn002){ref-type="table-fn"}   56.5 (42--66)                                                                             \-                                                                                        55--77
  Urea (mmol/L)                5.0 (4--6)         5.0 (4--5)                                                                                5.5 (5--9)                                                                              6.0 (5--7)          4.3 (3--7)                                             5.0 (4--6)                                                                                4.1 (4--6) [\*](#t006fn001){ref-type="table-fn"}                                          7.3 (5--8) [\*](#t006fn001){ref-type="table-fn"}[†](#t006fn002){ref-type="table-fn"}      13.2--27.1

\* indicates statistical significance at *p* \< 0.05 compared to saline alone.

† indicates statistical significance at *p* \< 0.05 compared to 5-FU alone.

Myeloperoxidase Activity {#sec014}
------------------------

There was no significant difference in MPO activity in either the jejunum or ileum when analgesics were administered to healthy control animals, indicating that the agents caused no adverse effects on inflammation at the given dosages.

Injection of 5-FU caused a significant (*p* \< 0.001) increase in MPO activity in the proximal jejunum and ileum of 5-FU control (1046% and 412% respectively) compared to saline control animals ([Fig 2](#pone.0158851.g002){ref-type="fig"}; see also [S3 File](#pone.0158851.s003){ref-type="supplementary-material"}). In the jejunum, both buprenorphine and tramadol caused a highly significant decrease in MPO activity in comparison with chemotherapy-treated control animals (53%, p = 0.0004 and 58%, p = 0.0001 respectively, [Fig 2A](#pone.0158851.g002){ref-type="fig"}). Analogously, in the ileum, tramadol reduced MPO activity by 31% (*p* = 0.003) in comparison to 5-FU controls. However, buprenorphine failed to have a similar ameliorating effect (*p* = 0.19, [Fig 2B](#pone.0158851.g002){ref-type="fig"}).

![Effect of analgesic agents on myeloperoxidase (MPO) activity in the jejunum (A) and ileum (B) 72 hr after either saline or 5-FU injection. Data are expressed as mean (MPO units/g tissue) ± SEM. \* indicates *p* \< 0.05 compared to saline + no analgesic and † *p* \< 0.05 compared to 5-FU + no analgesic.](pone.0158851.g002){#pone.0158851.g002}

Histological Severity Score {#sec015}
---------------------------

The histological architecture of the jejunum and ileum was entirely consistent with previous rat studies of mucositis, and included shortening of villi, crypt disruption, loss of goblet cells and enterocyte disruption ([Fig 3](#pone.0158851.g003){ref-type="fig"}). Chemotherapy administration significantly increased disease severity score in the proximal jejunum and ileum in all treated animals ([Fig 4](#pone.0158851.g004){ref-type="fig"}; see also [S4 File](#pone.0158851.s004){ref-type="supplementary-material"}) in comparison with saline-injected control animals (*p* \< 0.001 for all), thus determining that the mucositis condition was present. The analgesic agents had no effect on histological severity score in healthy animals or when given in conjunction with 5-FU ([Fig 4](#pone.0158851.g004){ref-type="fig"}).

![Representative photomicrographs (x 100) of the proximal jejunum sections stained with haematoxylin and eosin in animals treated with saline alone (A), 5-FU alone (B), 5-FU + carprofen (C), 5-FU + buprenorphine (D), 5-FU + tramadol (E).](pone.0158851.g003){#pone.0158851.g003}

![Effects of analgesic agents on disease severity score in the jejunum (A) and ileum (B) 72 hr after either saline or 5-FU injection. The severity scores were rated based on 8 parameters on different layers of intestinal tissues. The box plots represent the first and third quartiles, horizontal lines represent the median disease severity score and the whisker ends represent the maximum and minimum score. \* indicates *p* \< 0.05 compared to saline + no analgesic.](pone.0158851.g004){#pone.0158851.g004}

Villus Height and Crypt Depth Measurements {#sec016}
------------------------------------------

### Jejunal Effects {#sec017}

5-FU injection caused a shortening of the villi in the jejunum (36%, *P*\<0.001) compared to no analgesic saline controls ([Fig 5](#pone.0158851.g005){ref-type="fig"}; see also [S4 File](#pone.0158851.s004){ref-type="supplementary-material"}). Tramadol had a lengthening effect on villus height when administered with 5-FU, although this failed to attain significance. Administration of 5-FU caused no general reduction in crypt depth.

![Effects of analgesic agents on villus height and crypt depth in the jejunum (A) and ileum (B) 72 hr after either saline or 5-FU injection. VH = villus height, CD = crypt depth. Data are expressed as mean ± SEM. \* indicates *p* \< 0.05 compared to saline + no analgesic and † *p* \< 0.05 compared to 5-FU + no analgesic.](pone.0158851.g005){#pone.0158851.g005}

### Ileal Effects {#sec018}

Similarly, 5-FU caused a villus shortening in the ileum (40%, *p* = 0.005) compared to no analgesic saline controls ([Fig 5B](#pone.0158851.g005){ref-type="fig"}). Tramadol, when administered in the presence of 5-FU had a lengthening effect on villus height. This lengthening normalized villus heights towards values in saline treated (219 ± 18 v 270 ± 43 μm, respectively, *p* = 0.18, [Fig 5B](#pone.0158851.g005){ref-type="fig"}). However, it should be noted that the 5-FU + tramadol villus height values were not significant with respect to the 5-FU control group (*p* = 0.12, [Fig 5B](#pone.0158851.g005){ref-type="fig"}). Contrary to the results observed for jejunal tissue, 5-FU caused a general reduction in crypt depth when compared with that of saline control animals.

Discussion {#sec019}
==========

This study represents the first published investigation into analgesics administered to rats with experimentally-induced mucositis. The non-use of analgesia in these models potentially poses an ethical issue. However, an ethical issue also arises if an administered analgesic confounds data interpretation, resulting in misleading results and unnecessary study repetition. The current study indicated that all analgesics tested were efficacious against rat nociceptive behaviour. However, the opioid agonists had the potential to confound interpretation of study results due to an anti-inflammatory action. Therefore, in mucositis studies in which myeloperoxidase activity and histological parameters are the research outcomes of interest, carprofen is the preferred analgesic refinement.

Indeed, the opioid agents had more striking effects on the daily metabolic parameters and bodyweight than the NSAID. Importantly, bodyweight decreased after administration of either buprenorphine or tramadol in healthy animals, and these agents potentiated weight loss in animals with mucositis. This finding is likely to have arisen due to appetite suppression as a result of excess opioid activity, \[[@pone.0158851.ref029]\] postulated to be due to increased sedation or a nauseating effect. However, we failed to consistently demonstrate a similar decrease in food consumption in animals treated with these agents. The increase in drinking behaviour was expected since it is well established that μ-receptor activation leads to increased water intake, \[[@pone.0158851.ref030]\] although activation of this receptor also tends to lead to urinary retention, \[[@pone.0158851.ref031]\] rather than an increase in urination as demonstrated in the current study. The partial selectivity for this receptor by buprenorphine, and low receptor affinity by tramadol \[[@pone.0158851.ref032]\] therefore present significant clinical advantages of these drugs.

The analysis of occurrence of specific pain behaviours in rats is a well-validated pain assessment technique \[[@pone.0158851.ref021], [@pone.0158851.ref025], [@pone.0158851.ref033]\]. However, to date the applicability of the technique to models of chemotherapy-induced mucositis has only been reported once \[[@pone.0158851.ref011]\]. In the current study, intra-group differences across time were only evident in the 5-FU alone treated animals. There are two explanations for this finding; either 1) no pain was experienced by animals in all other groups and hence no change in score yielded, or 2) pain was experienced by animals with mucositis and was effectively managed at these time-points, hence no change in score was recorded. The latter interpretation is preferred for the 5-FU treated groups since the daily metabolic parameters and bodyweight data suggested that pathophysiological processes associated with mucositis development were occurring. The behavioural data provide evidence for the analgesics being present in plasma at a pharmacologically active level. This would however require confirmatory pharmacokinetic determination. Furthermore, by this interpretation it is concluded that, as previously determined, \[[@pone.0158851.ref021]\] the behaviours were truly pain-specific and not modified by drug-induced states such as sedation. Nevertheless, these conclusions are advanced cautiously since inter-group comparisons did not yield statistically significant differences between the chemotherapy-treated groups and saline control animals. However, given the inherent inter-individual variability in behaviour performance, and the subjective nature of the pain experience, comparison of values for the same animals across time may yield more accurate and relevant results. Use of less manually intensive automatic home-cage monitoring in future studies would allow comparison of a greater number of individuals at more time points to confirm these conclusions \[[@pone.0158851.ref034]\].

There is a significant body of literature demonstrating that opioids modulate immune responses \[[@pone.0158851.ref035]\]. Chronic administration of opioids to rodents has been demonstrated to lead to thymic and splenic atrophy, \[[@pone.0158851.ref036]--[@pone.0158851.ref038]\] and elevation of CD4+/CD8+ ratios, \[[@pone.0158851.ref038]\] yet other studies in rats have demonstrated an increase in spleen weight \[[@pone.0158851.ref039]\]. Such effects may be brought about through direct suppression of natural killer cell activity via opiate receptors, or indirectly through modulating cytokine release, \[[@pone.0158851.ref040]\] or induction of corticosteroids \[[@pone.0158851.ref041]\]. However, buprenorphine has minimal immunosuppressive action \[[@pone.0158851.ref042], [@pone.0158851.ref043]\]. Since the splenic weight decrease reported in the current study only occurred when co-administered with 5-FU there may have been a synergistic effect, possibly driven via the chemotherapy-induced inflammatory response, and the consequent Hypothalamic Pituitary Axis induced increase in corticosterone, \[[@pone.0158851.ref044]\] or as a direct immunosuppressive effect of 5-FU. Consistent with our results, opioids have previously been shown to decrease liver weights and increase kidney weights *in vivo* \[[@pone.0158851.ref039]\]. A decrease in hepatic vacuolization due to reduced food intake and hence glycogen storage may explain the former finding \[[@pone.0158851.ref039]\]. The increase in renal and hepatic weight in carprofen-treated animals is postulated to be a result of the drug clearance activities of these organs. It is noteworthy that despite the previously referred to changes in organ weights, serum biochemistry confirmed there were no organ functional changes. Opioids tend to contract intestinal muscle via direct activation of muscle cells, \[[@pone.0158851.ref045]\] or depression of nitric oxide release from enteric neurons \[[@pone.0158851.ref046]\]. The finding of an increased colon length in the tramadol group is therefore inconsistent but may reflect the differential selectivity of buprenorphine and tramadol for the μ-opioid receptor.

Myeloperoxidase enzyme levels provide a measure of neutrophil influx and hence acute inflammation \[[@pone.0158851.ref023]\]. Administration of the opioid analgesics had an anti-inflammatory effect as evidenced through the substantial reduction in myeloperoxidase activity. This effect is assumed to be as a result of the μ-receptor agonism since a similar effect has been noted previously \[[@pone.0158851.ref047]\]. This is of interest since opioid receptor agonists are generally assumed to have poor, or at least misunderstood anti-inflammatory action \[[@pone.0158851.ref048]\]. To our knowledge, this is the first report of this finding in chemotherapy-induced mucositis. In order to confirm this mechanism and determine the magnitude of it future studies should incorporate a μ- receptor antagonist agent.

Interestingly, the NSAID carprofen failed to attenuate the MPO response. This attests to the selectivity of NSAID agents in preventing the production of inflammatory mediators such as prostaglandins and leukotrienes via inhibition of the cyclooxygenase pathway \[[@pone.0158851.ref049]\]. However, phagocytosing polymorphonuclear leucocytes produce H~2~O~2~ and chloride. The interaction between H~2~O~2~ and chloride ions with MPO releases oxidant products. These oxidant products are likely to be important inflammatory mediators \[[@pone.0158851.ref049]\]. Therefore, in spite of the blockade of cyclooxygenase by NSAIDs, an inflammatory effect could still be produced via this alternate oxidant pathway \[[@pone.0158851.ref049]\]. Therefore the ideal NSAID would not only have effects on the cyclooxygenase pathway, but anti-oxidant/free radical scavenging ability in addition. Whilst it has been demonstrated that a range of NSAIDS target polymorphonuclear MPO via their free radical scavenging effects, \[[@pone.0158851.ref049]\] our data suggest that carprofen was unable to exert this effect. Since, myeloperoxidase activity is commonly used to measure therapeutic effect in trials of new therapeutic agents against mucositis, carprofen is rendered the drug of choice by this finding.

Despite, the beneficial reduction in MPO activity caused by the opioid agents, in the current study, there was no corresponding decrease in histological severity score. However, tramadol as the most efficacious agent in reducing MPO, showed a trend towards restoration of villus height. It is noteworthy that this effect also occurred in healthy animals and is previously unreported. In order to fully understand the inflammatory processes occurring in chemotherapy-induced mucositis, their relation to histological repair and synergism between therapeutics, future studies should investigate a range of inflammatory markers such as the pro-inflammatory cytokines and cyclooxygenase activity.

Mechanisms of pain production by cytotoxic agents in gastrointestinal mucositis are poorly understood, \[[@pone.0158851.ref050]\] yet pain remains one of the key dose-limiting factors for patients \[[@pone.0158851.ref051]\]. However, research effort in this area is likely to increase since the discovery that: 1) chemotherapy-related hyperalgesia can be reversed by immunomodulatory agents \[[@pone.0158851.ref051]\]; and 2) there is a high level of μ-opioid receptor expression in the intestinal tract, particularly during inflammation \[[@pone.0158851.ref047]\]. Therefore, the ability to reliably measure affective pain as opposed to nociception is a much needed animal model refinement. This study has indicated that behavioural pain assessment scoring may be one such tool but does require further validation. Our data do however raise some concerns with the ability of the model to replicate the human mucositis condition; if human patients frequently require morphinomimetic agents to control pain, \[[@pone.0158851.ref052]\] yet rat pain is controlled by less potent opioids or NSAIDs, is the subjective pain experience of both these species too different to reconcile *or*, is there a possibility that partial opioid agonists, NSAIDs, or a combination thereof, are under-utilized in human oncologic practice.

In conclusion, this study has provided evidence that carprofen is efficacious against pain, and produces minimal interference with research outcomes, in a rat model of chemotherapy-induced mucositis. Furthermore, the identification of intestinal anti-inflammatory activity of μ- receptor opioid agonists supports further pre-clinical investigation into opioid agents with non-traditional pharmacological actions, such as partial agonists, atypical agents, or peripherally-acting agents \[[@pone.0158851.ref047]\].
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###### Behavioural data used in [Fig 1](#pone.0158851.g001){ref-type="fig"} and [Table 3](#pone.0158851.t003){ref-type="table"}.
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###### Myeloperoxidase data used in [Fig 2](#pone.0158851.g002){ref-type="fig"}.
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###### Histological data used in Figs [4](#pone.0158851.g004){ref-type="fig"} and [5](#pone.0158851.g005){ref-type="fig"}.

(XLSX)
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Click here for additional data file.
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